protocolSection identificationModule nctId: NCT06378047, orgStudyIdInfo id: MCC-22325, briefTitle: Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-10, primaryCompletionDateStruct date: 2027-04, completionDateStruct date: 2027-04, studyFirstPostDateStruct date: 2024-04-22, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: H. Lee Moffitt Cancer Center and Research Institute, class: OTHER, collaborators name: Angiodynamics, Inc., descriptionModule briefSummary: This study aims to determine the safety and tolerability of combining sequential therapy of Irreversible Electroporation (IRE) and Immunotherapy (IO) for patients with locally advanced unresectable pancreas cancer following first-line treatment with chemotherapy and ablative stereotactic magnetic resonance image-guided adaptive radiation therapy (A-SMART)., conditionsModule conditions: Pancreatic Cancer, conditions: Locally Advanced Pancreatic Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 3, type: ESTIMATED, armsInterventionsModule interventions name: Pembrolizumab, interventions name: Irreversible Electroporation, outcomesModule primaryOutcomes measure: Safety and Tolerability, secondaryOutcomes measure: Progression-Free Survival (PFS), secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Objective Response Rate (ORR), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Moffitt Cancer Center, status: RECRUITING, city: Tampa, state: Florida, zip: 33612, country: United States, contacts name: Alicia Chin, role: CONTACT, phone: 813-745-4673, email: Alicia.Chin@moffitt.org, contacts name: Victoria Kryliouk, role: CONTACT, email: Victoria.Kryliouk@moffitt.org, contacts name: Mokenge Malafa, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Mohammed Al-Jumayli, MD, role: SUB_INVESTIGATOR, contacts name: Junsung Choi, MD, role: SUB_INVESTIGATOR, contacts name: James Costello, MD, PhD, role: SUB_INVESTIGATOR, contacts name: Aamir Dam, MD, role: SUB_INVESTIGATOR, contacts name: Jason Denbo, MD, role: SUB_INVESTIGATOR, contacts name: Sophie Dessureault, MD, PhD, role: SUB_INVESTIGATOR, contacts name: Martine Extermann, MD, PhD, role: SUB_INVESTIGATOR, contacts name: Jessica Frakes, MD, role: SUB_INVESTIGATOR, contacts name: Pamela Hodul, MD, role: SUB_INVESTIGATOR, contacts name: Sarah Hoffe, MD, role: SUB_INVESTIGATOR, contacts name: Dae Won Kim, MD, role: SUB_INVESTIGATOR, contacts name: Richard Kim, MD, role: SUB_INVESTIGATOR, contacts name: Bela Kis, MD, PhD, role: SUB_INVESTIGATOR, contacts name: Allan Lima Pereira, MD, PhD, role: SUB_INVESTIGATOR, contacts name: Shaffer Mok, MD, role: SUB_INVESTIGATOR, contacts name: Russell Palm, MD, role: SUB_INVESTIGATOR, contacts name: Jose Pimiento, MD, role: SUB_INVESTIGATOR, contacts name: Paulo Rodriguez, PhD, role: SUB_INVESTIGATOR, contacts name: Christine Sam, MD, role: SUB_INVESTIGATOR, contacts name: Andrew Sinnamon, MD, role: SUB_INVESTIGATOR, contacts name: Amalia Stefanou, MD, role: SUB_INVESTIGATOR, contacts name: Jonathan Strosberg, MD, role: SUB_INVESTIGATOR, geoPoint lat: 27.94752, lon: -82.45843, hasResults: False